Acknowledgments Disclosure Statement rateful to miss Ute Gitzen and Miss Tani LB..LH..LL.and KP.have nothing to disclose:S.HP.con sults for Apitope,and G.J.K.consults for Apitope and Quidel. References atior D:Gra N Eng d o antibod ront Endocrine 14 Lee HI.Li CW,Ha ad M. Bagnasco M.Giavarina D.Bizzaro with Gr 15 IC Ender for and preva eta-analysis.Auto 26 Bic 27 S.I 16 waT, DS.Bur B. Coope DS.Greenle e e auchi A ke arca vs.high o ansen PS.Ky G]:Novel chim 18 it GH.Mor T.Klasen R.Oliyo PD Ka haly G]:A gradin ng and lating activity erri El SH' d autoanti in the diag 山 A.o 52 opin assay to s al relevans th ing h Kahaly/Bartalena/Hegeduis/Leenhardt/ Poppe/Pearce 医通 http://guide.medlive.cn/ Kahaly/Bartalena/Hegedüs/Leenhardt/ Poppe/Pearce 182 Eur Thyroid J 2018;7:167–186 DOI: 10.1159/000490384 Acknowledgments The authors are grateful to Miss Ute Gitzen and Miss Tanja Diana, MSc, PhD, Thyroid Research Lab, JGU Medical Center, Mainz, Germany, for their valuable help in coediting the manu￾script and compiling the reference list using Endnote software. Disclosure Statement L.B., L.H., L.L., and K.P. have nothing to disclose; S.H.P. con￾sults for Apitope, and G.J.K. consults for Apitope and Quidel. References 1 Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN; American Thyroid Association; American Association of Clinical Endocri￾nologists: Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocri￾nologists. Endocr Pract 2011;17:456–520. 2 Bartalena L: Diagnosis and management of Graves disease: a global overview. Nat Rev En￾docrinol 2013;9:724–734. 3 Kahaly GJ, Dillmann WH: Thyroid hormone action in the heart. Endocr Rev 2005;26:704– 728. 4 Biondi B, Kahaly GJ: Cardiovascular involve￾ment in patients with different causes of hy￾perthyroidism. Nat Rev Endocrinol 2010;6: 431–443. 5 Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samu￾els M, Sosa JA, Stan MN, Walter MA: 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroid￾ism and other causes of thyrotoxicosis. Thy￾roid 2016;26:1343–1421. 6 Smith TJ, Hegedus L: Graves’ disease. N Engl J Med 2016;375:1552–1565. 7 Nystrom HF, Jansson S, Berg G: Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Swe￾den (Gothenburg) 2003–2005. Clin Endocri￾nol 2013;78:768–776. 8 McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S: Variation in rates of autoim￾mune thyroid disease by race/ethnicity in US military personnel. JAMA 2014;311:1563– 1565. 9 Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM: The thyrotropin (TSH) re￾ceptor: interaction with TSH and autoanti￾bodies. Endocr Rev 1998;19:673–716. 10 Rapoport B, McLachlan SM: TSH receptor cleavage into subunits and shedding of the A￾subunit; a molecular and clinical perspective. Endocr Rev 2016;37:114–134. 11 Smith TJ, Hegedus L, Douglas RS: Role of in￾sulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 2012;26: 291–302. 12 Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001;86:930–934. 13 Inaba H, De Groot LJ, Akamizu T: Thyrotro￾pin receptor epitope and human leukocyte antigen in Graves’ disease. Front Endocrinol 2016;7:120. 14 Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y: Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun 2015;64:82–90. 15 Strieder TG, Prummel MF, Tijssen JG, Endert E, Wiersinga WM: Risk factors for and preva￾lence of thyroid disorders in a cross-sectional study among healthy female relatives of pa￾tients with autoimmune thyroid disease. Clin Endocrinol 2003;59:396–401. 16 Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G: High incidence of multinodu￾lar toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotox￾icosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991;229:415–420. 17 Brix TH, Hansen PS, Kyvik KO, Hegedus L: Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med 2000; 160:661–666. 18 Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Monto￾ri VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, develop￾ment, and evaluation system. J Clin Endocri￾nol Metab 2008;93:666–673. 19 de los Santos ET, Starich GH, Mazzaferri EL: Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diag￾nosis of thyroid disease in ambulatory pa￾tients. Arch Intern Med 1989;149:526–532. 20 Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, Gray D, Nicoloff JT: Appli￾cations of a new chemiluminometric thyro￾tropin assay to subnormal measurement. J Clin Endocrinol Metab 1990;70:453–460. 21 Grebe SK, Kahaly GJ: Laboratory testing in hyperthyroidism. Am J Med 2012;125:S2. 22 Bartalena L, Burch HB, Burman KD, Kahaly GJ: A 2013 European survey of clinical prac￾tice patterns in the management of Graves’ disease. Clin Endocrinol 2016;84:115–120. 23 Kahaly GJ, Olivo PD: Graves’ disease. N Engl J Med 2017;376:184. 24 Kahaly GJ, Diana T: TSH receptor antibody functionality and nomenclature. Front Endo￾crinol 2017;8:28. 25 Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N: TSH receptor autoantibody immunoassay in patients with Graves’ disease: improve￾ment of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev 2012;12: 107–113. 26 Kahaly GJ: Bioassays for TSH receptor anti￾bodies: quo vadis? Eur Thyroid J 2015;4:3–5. 27 Araki N, Iida M, Amino N, Morita S, Ide A, Nishihara E, Ito M, Saito J, Nishikawa T, Kat￾suragi K, Miyauchi A: Rapid bioassay for de￾tection of thyroid-stimulating antibodies us￾ing cyclic adenosine monophosphate-gated calcium channel and aequorin. Eur Thyroid J 2015;4:14–19. 28 Lytton SD, Kahaly GJ: Bioassays for TSH-re￾ceptor autoantibodies: an update. Autoim￾mun Rev 2010;10:116–122. 29 Lytton SD, Li Y, Olivo PD, Kohn LD, Kahaly GJ: Novel chimeric thyroid-stimulating hor￾mone-receptor bioassay for thyroid-stimulat￾ing immunoglobulins. Clin Exp Immunol 2010;162:438–446. 30 Li Y, Kim J, Diana T, Klasen R, Olivo PD, Ka￾haly GJ: A novel bioassay for anti-thyrotro￾phin receptor autoantibodies detects both thyroid-blocking and stimulating activity. Clin Exp Immunol 2013;173:390–397. 31 Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, Kahaly GJ: Standardization of a bioassay for thyrotropin receptor stimulating autoan￾tibodies. Thyroid 2015;25:169–175. 32 Diana T, Li Y, Olivo PD, Lackner KJ, Kim H, Kanitz M, Kahaly GJ: Analytical performance and validation of a bioassay for thyroid￾blocking antibodies. Thyroid 2016;26:734– 740. 33 Diana T, Krause J, Olivo PD, Konig J, Kanitz M, Decallonne B, Kahaly GJ: Prevalence and clinical relevance of thyroid stimulating hor￾mone receptor-blocking antibodies in auto￾immune thyroid disease. Clin Exp Immunol 2017;189:304–309. http://guide.medlive.cn/